Standorte / Kliniken / Häuser
Unternehmen
Publications - Titelbild

Publications

Publications & Patents

References:

  1. Mavroeidi IA, Romanowicz A, Haake T, Wienker J, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Opitz M, Nader M, Hamacher R, Siveke J, Winantea J, Fendler WP, Wiesweg M, Eberhardt WEE, Herrmann K, Theegarten D, Schuler M, Hautzel H, Kersting D. Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival. Theranostics. 2024 Aug 26;14(14):5400-5412. doi: 10.7150/thno.98819. PMID: 39310095; PMCID: PMC11413793.
  2. Pabst KM., Kessler L., Ferdinandus J., Hamacher R., Bartel T., Siveke JT., Nader M., Brandenburg T., Desaulniers M., Herrmann K., Fendler WP. [68Ga]Ga-FAPI versus 2-[18F]FDG PET/CT in patients with autoimmune thyroiditis: a case control study. EJNMMI Res. 2024 Jul 18;14(1):66. doi: 10.1186/s13550-024-01129-y. PMID: 39023777; PMCID: PMC11258103.
  3. Kessler L., Schwaning F., Metzenmacher M., Pabst K., Siveke J., Trajkovic-Arsic M., Schaarschmidt B., Wiesweg M., Aigner C., Plönes T., Darwiche K., Bölükbas S., Stuschke M., Umutlu L., Nader M., Theegarten D., Hamacher R., Eberhardt W.E.E., Schuler M., Herrmann K., Fendler W.P., Hautzel H.. Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial. J Nucl Med. 2024 Aug 1;65(8):1188-1193. doi: 10.2967/jnumed.124.267473. PMID: 38960716.
  4. Lanzafame H., Mavroeidi I.A., Pabst K.M., Desaulniers M., Ingenwerth M., Hirmas N., Kessler L., Nader M., Bartel T., Leyser S., Barbato F., Schuler M., Bauer S., Siveke J.T., Herrmann K., Hamacher R., Fendler W.P. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy. J Nucl Med. 2024 Jun 3;65(6):880-887. doi: 10.2967/jnumed.123.267248. PMID: 38724279.
  5. Kupusovic J., Kessler L., Kazek S., Chodyla M.K., Umutlu L., Zarrad F., Nader M., Fendler W.P., Varasteh Z., Hermann K., Dobrev D., Wakili R., Rassaf T., Siebermair J., Rischpler C. Delayed 68Ga-FAPI-46 PET/MR imaging confirms ongoing fibroblast activation in patients after acute myocardial infarction. Int J Cardiol Heart Vasc. 2024 Jan 23;50:101340. doi: 10.1016/j.ijcha.2024.101340. PMID: 38313450; PMCID: PMC10835345.
  6. Hirmas N., Hamacher R., Sraieb M., Kessler L., Pabst K.M., Barbato F., Lanzafame H., Kasper S., Nader M., Kesch C., von Tresckow B., Hautzel H., Aigner C., Glas M., Stuschke M., Kümmel S., Harter P., Lugnier C., Uhl W., Hadaschik B., Grünwald V., Siveke J.T., Herrmann K., Fendler W.P. Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies. J Nucl Med. 2024 Mar 1;65(3):372-378. doi: 10.2967/jnumed.123.266652. Epub 2024 Feb 8. PMID: 38331453..
  7. Kersting D., Sandach P., Sraieb M., Wiesweg M., Metzenmacher M., Darwiche K, Oezkan F., Bölükbas S., Stuschke M., Umutlu L., Nader M., Hamacher R., Fendler W.P., Wienker J., Eberhardt W.E.E., Schuler M., Herrmann K., Hautzel H. 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study. J Nucl Med. 2023 Oct;64(10):1540-1549. doi: 10.2967/jnumed.123.265664. Epub 2023 Jul 20. PMID: 37474272.
  8. Kessler L., Hirmas N., Pabst K.M., Hamacher R., Ferdinandus J., Schaarschmidt B.M., Milosevic A., Nader M., Umutlu L., Uhl W., Reinacher-Schick A., Lugnier C, Witte D., Niedergethmann M., Herrmann K., Fendler W.P., Siveke J.T. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. J Nucl Med. 2023 Dec 1;64(12):1910-1917. doi: 10.2967/jnumed.122.264827. PMID: 37973185.
  9. Pabst K.M., Trajkovic-Arsic M., Cheung P.F.Y., Ballke S., Steiger K., Bartel T., Schaarschmidt B.M., Milosevic A., Seifert R., Nader M., Kessler L., Siveke J.T., Lueckerath K., Kasper S., Herrmann K., Hirmas N., Schmidt H.H., Hamacher R., Fendler W.P. Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. J Nucl Med. 2023 Jul;64(7):1049-1055. doi: 10.2967/jnumed.122.265215. Epub 2023 Apr 6. PMID: 37024301; PMCID: PMC10315700.
  10. Hirmas N., Hamacher R., Sraieb M., Ingenwerth M., Kessler L., Pabst K.M., Barbato F., Lueckerath K., Kasper S., Nader M., Schildhaus H.U., Kesch C., von Tresckow B., Hanoun C., Hautzel H., Aigner C., Glas M., Stuschke M., Kümmel S., Harter P., Lugnier C., Uhl W., Niedergethmann M., Hadaschik B., Grünwald V., Siveke J.T., Herrmann K., Fendler W.P. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities. J Nucl Med. 2023 May;64(5):711-716. doi: 10.2967/jnumed.122.264689. Epub 2022 Dec 29. PMID: 36581374.
  11. Seifert R., Telli T., Opitz M., Barbato F., Berliner C., Nader M., Umutlu L., Stuschke M., Hadaschik B, Herrmann K., Fendler W.P. Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2023 May;64(5):738-743. doi: 10.2967/jnumed.118.215434. Epub 2022 Dec 2. PMID: 36460340.
  12. Costa P.F., Püllen L., Kesch C., Krafft U., Tschirdewahn S., Moraitis A., Radtke J.P., Ting S., Nader M., Wosniack J., Kersting D., Lückerath K., Herrmann K., Fendler W.P., Hadaschik B.A., Darr C. 18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in Men. J Nucl Med. 2023 Apr;64(4):598-604. doi: 10.2967/jnumed.122.264670. Epub 2022 Nov 10. PMID: 36357181.
  13. Nader M., K. Herrmann, F. Kunkel, F. Zarrad, A. Pacelli, W., Fendler, S. Koplin Improved production of 68Ga-Pentixafor using cartridge mediated cation exchange purification. Appl. Radiat. Isot. 2022; 189: 110447. DOI:10.1016/j.apradiso.2022.110447.
  14. Civan C., Kasper S., Berliner C., Fragoso-Costa P., Grünwald V., Pogorzelski M., Schaarschmidt B.M., Lang S., Kersting D., Nader M., Lückerath K., Herrmann K., Fendler W.P., Weber M. PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study. J Nucl Med. 2023 Mar;64(3):372-378. doi: 10.2967/jnumed.122.264342. Epub 2022 Sep 22. PMID: 36137757; PMCID: PMC10071793.
  15. Laschinsky C., Herrmann K., Fendler W., Nader M., Lahner H., Hadaschik B., Sandach P. Onkologische Theranostik in der Nuklearmedizin [Oncological theranostics in nuclear medicine]. Radiologie (Heidelb). 2022 Oct;62(10):875-884. German. doi: 10.1007/s00117-022-01072-w. PMID: 36112174.
  16. Pacelli A., Zarrad F., Fendler W. P., Herrmann K., Nader M. Fully automated, high-dose radiosynthesis of [18F]PARPi. Pharmaceuticals. 2022, 15(7), 865.https://doi.org/10.3390/ph15070865
  17. Nader M., Valla D., Vriamont C.F., Masset J, Pacelli A., Herrmann K., Zarrad F. [68Ga]/[90Y]FAPI-46: Automated Production and Analytical Validation of a Theranostic Pair. Nucl. Med. Biol. 2022; 110: 37-44. doi.org/10.1016/j.nucmedbio.2022.04.010
  18. Kersting D., Sraieb M., Seifert R., Costa P.F., Kazek S., Kessler L., Umutlu L., Fendler W.P., Jentzen W., Herrmann K., Büther F., Nader M., Rischpler C. First experiences with dynamic renal [68Ga]Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate. Eur J Nucl Med Mol Imaging. 2022 Apr 12;1-14. doi: 10.1007/s00259-022-05781-1.
  19. Kessler L., Ferdinandus J., Hirmas N., Zarrad F., 1, Nader M., Kersting D., Weber M., Kazek S., Sraieb M., Hamacher R., Lueckerath K., Umutlu L., Fendler W., Rischpler C. J. Pitfalls and common findings in 68Ga-FAPI-PET – A pictorial analysis. Nucl. Med. 2022 63(6): 890-896. doi: 10.2967/jnumed.121.262808.
  20. Kessler L, Ferdinandus J, Hirmas N, Bauer S, Dirksen U, Zarrad F, Nader M, Chodyla MK, Milosevic A, Umutlu L, Schuler M, Podleska LE, Schildhaus HU, Fendler WP, Hamacher R. Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial. J Nucl Med. 2022 Jan;63(1):89-95. doi: 10.2967/jnumed.121.262096.
  21. Barbato F, Fendler WP, Rauscher I, Herrmann K, Wetter A, Ferdinandus J, Seifert R, Nader M, Rahbar K, Hadaschik B, Eiber M, Gafita A, Weber. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease..J Nucl Med. 2021 May 62(12): 1747-1750. doi: 10.2967/jnumed.121.262120. Online ahead of print.PMID: 33990403.
  22. Kessler L, Kupusovic J, Ferdinandus J, Hirmas N, Umutlu L, Zarrad F, Nader M, Fendler WP, Totzeck M, Wakili R, Schlosser T, Rassaf T, Rischpler C, Siebermair J. Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET. Clin Nucl Med. 2021 Oct 1;46(10):807-813. doi: 10.1097/RLU.0000000000003745.
  23. Kersting D., Jentzen W., Sraieb M., Costa F. P., Conti M., Umutlu L, Antoch G., Nader M., Herrmann K., Fendler W. P., Rischpler C., Weber M. Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. EJNMMI Phys. 2021 Feb 15;8(1):14. doi: 10.1186/s40658-021-00361-y.
  24. Hirmas N., Leyh C., Sraieb M., Barbato F., Schaarschmidt B., Umutlu L., Nader M., Wedemeyer H., Ferdinandus J., Rischpler C., Herrmann K., Costa P., Lange C., Weber M., Fendler W. 68Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC). J Nucl Med 2021 Sep 1;62(9):1235-1241. doi: 10.2967/jnumed.120.257915.
  25. Weber M., Kurek C. E., Barbato F., Eiber M., Maurer T., Nader M., Hadaschik B., Grünwald V., Herrmann K., Wetter A., Fendler W. F. PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study. J Nucl Med 2021 Jan;62(1):88-91. http://dx.doi.org/10.2967/jnumed.120.245456
  26. Barth M., Dunzinger A., Wimmer I., Winkler J., Rittmannsberger H., Nader M., Pichler R. Serotonin 1A receptor density measured by F18-Mefway PET/CT in mesiotemporal cortex and raphe does not discriminate therapeutic response in patients with major depressive episode. Q J Nucl Med Mol Imaging 2020;64(2):203-210. http://dx.doi.org/10.23736/S1824-4785.18.03039-X
  27. Nader M., Oberdorfer F., Herrmann K. Production of [11C]Formaldehyde by the XeF2 mediated Oxidation of [11C]Methanol and its Application in the Labelling of a-(N-[11C]Methyl-amino)-isobutyric Acid. Appl. Radiat. Isot. 2019; 148: 178-183. http://dx.doi.org/10.1016/j.apradiso.2019.03.032
  28. Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W. Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics. J. Nucl. Med. 2013; 54: 833-40. http://dx.doi.org/10.2967/jnumed.112.110148
  29. Beheshti M., Vali R., Waldenberger P., Fitz F., Nader M., Loidl W., Broinger G., Stoiber F., Foglman I., Langsteger W., Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study. Eur J Nucl Med Mol Imaging, 2012; 35:1766-1774. http://dx.doi.org/10.1007/s00259-008-0788-z
  30. Nader M., Reindl D., Eichinger R., Beheshti M., Langsteger W. Improved Quality Control of [18F]Fluoromethylcholine.  Nucl. Med. Biol. 2011; 38(8):1143-1148. http://dx.doi.org/10.1016/j.nucmedbio.2011.05.006
  31. Nader M., Oberdorfer F. [11C]Lithium trimethylsilyl ynolate: a new [11C] precursor and its application in heterocyclic synthesis. Tetrahedron Lett. 2011; 52 (18): 2309-2311. https://doi.org/10.1016/j.tetlet.2011.02.066
  32. Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254(3):925-33. http://dx.doi.org/10.1148/radiol.09090413
  33. Beheshti M., Vali R., Waldenberger P., Fitz F., Nader M., Hammer J., Loidl W., Pirich C., Fogelman I., Langsteger W. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Mol Imaging Biol. 2010; 12(1):98-107. http://dx.doi.org/10.1007/s11307-009-0239-7
  34. Beheshti M., Reza Vali R., Waldenberger P, Fitz F., Nader M., Hammer J., Loidl W., Pirich C., Fogelman I., Langsteger W. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Mol Imaging Biol 2009 Nov-Dec;11(6):446-54. http://dx.doi.org/10.1007/s11307-009-0217-0
  35. Beheshti M., Pöcher S., Vali R., Waldenberger P., Broinger G., Nader M., Kohlfürst S., Pirich C., Dralle H., Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radiol. 2009;19(6):1425-1434. http://dx.doi.org/10.1007/s00330-008-1280-7
  36. Beheshti M., Vali R., Waldenberger P., Fitz F., Nader M., Loidl W., Broinger G., Stoiber F., Foglman I., Langsteger W. Detection of bone metastases in patients with prostate cancer by 18F-fluorocholine and 18F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35(10):1766-1774. http://dx.doi.org/10.1007/s00259-008-0788-z
  37. Krasikova R. N., Zaitsev V. V, Ametamey S. M, Kuznetsova OF, Fedorova OS, Mosevich I. K, Belokon Y. N, Vyskocil S., Shatik S. V., Nader M., Schubiger P. A. Catalytic enantioselective synthesis of 18F-fluorinated alpha-amino acids under phase-transfer conditions using (S)-NOBIN. Nucl. Med. Biol. 2004;31(5):597-603. https://doi.org/10.1016/j.nucmedbio.2003.12.010
  38. Kuznetsova O. F., Fedorova O. S., Vasilev D. A., Simonova T. P., Nader M., Krasikova R. N. Preparation and Quality Control of [N-Methyl-11C]choline for Routine PET Application. Radiochemistry, 2003; 45: 377-381. https://doi.org/10.1023/A:1026113604743
  39. Nader M., Oberdorfer F., Syntheses of [carbonyl-11C]2-(2-benzoylphenoxy)-N-phenylacetamide from [11C]carbon monoxide by the Suzuki and the Stille reactions. Appl. Radiat. Isot. 2002; 57: 681-685. https://doi.org/10.1016/S0969-8043(02)00183-5
  40. McKinney C. J., Nader M. A Peltier Thermal Cycling Unit for Rapid Radiopharmaceutical Synthesis Appl. Radiat. Isot. 2001; 54; 97-100. http://dx.doi.org/10.1016/S0969-8043.
  41. Zeisler, S., Nader, M., Theobald, A., Oberdorfer, F. (1997). Conversion of no-carrier-added [11C]carbon dioxide to [11C]carbon monoxide on molybdenum for the synthesis of 11C-labelled aromatic ketones. Applied Radiation and Isotopes, 48(8), 1091-1095. https://doi.org/10.1016/s0969-8043(97)00109-7.

Patent

Valve having a deformable part and use of the valve

Publication Number: US-9611942-B2 

Inventor(s): Schubert Michael; Busch Reinhard; Nader Michael